Next Generation of Rapid Diagnostics
OUR TECHNOLOGY
At Antibody Design, we use AI neural networks to develop smartphone compatible immuno-detection assays. Having identified a valuable opportunity in digitalisation, we are currently using our platform on a novel point-of-care, rapid action tool that can aid the diagnosis and treatment of influenza virus. Our platform technology can be applied to a wide range of medical, environmental and agricultural test beds.
CASE STUDY
Current diagnostic tests for Influenza virus use antibodies that target nuclear proteins. Since they are inside of the virus they are difficult to detect and the average sensitivity is 50%.
Antibody Design instead targets conserved and universally present proteins on the surface of the virus, and quantum dot coupled digital capture, leading to a better detection.
